The bioavailability of subcutaneous injectable erythropoietin is much lower than that of the intravenous medicinal product and is approximately 20%.
A subcutan injektált eritropoetin hasznosulása sokkal alacsonyabb, mint az intravénás gyógyszeré: mintegy 20%.